Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
Open accessThe DOI matches its Crossref record; 330 of the 330 references it cites were found in a registry or an index.
Abstract
Macrophages are ancient, phagocytic immune cells thought to have their origins 500 million years ago in metazoan phylogeny. The understanding of macrophages has evolved to encompass their foundational roles in development, homeostasis, tissue repair, inflammation, and immunity. Notably, macrophages display high plasticity in response to environmental cues, capable of a strikingly wide variety of dynamic gene signatures and phenotypes. Macrophages are also involved in many pathological states including neural disease, asthma, liver disease, heart disease, cancer, and others. In cancer, most tumor-associated immune cells are macrophages, coined tumor-associated macrophages (TAMs). While some TAMs can display anti-tumor properties such as phagocytizing tumor cells and orchestrating an immune response, most macrophages in the tumor microenvironment are immunosuppressive and pro-tumorigenic. Macrophages have been implicated in all stages of cancer. Therefore, interest in manipulating macrophages as a therapeutic strategy against cancer developed as early as the 1970s. Companion dogs are a strong comparative immuno-oncology model for people due to documented similarities in the immune system and spontaneous cancers between the species. Data from clinical trials in humans and dogs can be leveraged to further scientific advancements that benefit both species. This review aims to provide a summary of the current state of knowledge on macrophages in general, and an in-depth review of macrophages as a therapeutic strategy against cancer in humans and companion dogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“engineered CAR-Ms have leaded to increase of anti-tumor cytokines, such as IL-6, and chemokines, such as CXCL18, in the TME of osteosarcoma [138, 139].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [138]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–330 of 330
Sorenmo, K. U., Krick, E., Coughlin, C. M., Overley, B., Gregor, T. P., Vonderheide, R. H., & Mason, N. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024167 · Cited by 75
Perry, J. A., Thamm, D. H., Eickhoff, J. C., Avery, A. C., & DOW, S. W. (2010) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2010.00235.x · Cited by 73
Self-citationDefining the Value of a Comparative Approach to Cancer Drug Development
LeBlanc, A. K., Mazcko, C. N., & Khanna, C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2347 · Cited by 73 · cited 1×
“Companion dogs are a strong comparative immunooncology model for people due to documented similarities of the immune system and spontaneous cancers between the species (14).”
BackgroundRegan, D. P., Coy, J. W., Chahal, K. K., Chow, L., Kurihara, J. N., Guth, A. M., Kufareva, I., & Dow, S. W. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800619 · Cited by 73
Biomechanical Contributions to Macrophage Activation in the Tumor Microenvironment
Hoffmann, E. J., & Ponik, S. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00787 · Cited by 73 · cited 1×
“) in the TME contributes to TAM polarization and function (106).”
BackgroundMonteiro, L. N., Rodrigues, M. Â., Gomes, D. A., Salgado, B. S., & Cassali, G. D. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2018.02.016 · Cited by 72
Wang, H., Shao, Q., Sun, J., Ma, C., Gao, W., Wang, Q., Zhao, L., & Qu, X. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1122157 · Cited by 71
Li, Y., Zhi-hu, S., Wang, X., Gu, K., & Zhai, Z. (2019) · BMC Cancer · doi:10.1186/s12885-019-6208-x · Cited by 71 · cited 1×
“Lymphoma Advanced stage, decreased OS (129, 130) High-grade disease (131)”
BackgroundClinical and molecular insights into BCG immunotherapy for melanoma
Kremenovic, M., Schenk, M., & Lee, D. J. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13037 · Cited by 70
Ardighieri, L., Missale, F., Bugatti, M., Gatta, L. B., Pezzali, I., Monti, M., Gottardi, S., Zanotti, L., Bignotti, E., Ravaggi, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690201 · Cited by 69
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines
Sayour, E. J., & Mitchell, D. A. (2017) · Journal of Immunology Research · doi:10.1155/2017/3145742 · Cited by 67
Sottnik, J. L., Rao, S., Lafferty, M. H., Thamm, D. H., Morley, P. S., Withrow, S. J., & Dow, S. W. (2010) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2010.0591.x · Cited by 66
Self-citationEvaluation of a Novel Tumor Vaccine in Dogs with Hemangiosarcoma
U’Ren, L., Biller, B. J., Elmslie, R. E., et al. (2007) · Journal of Veterinary Internal Medicine · doi:10.1892/0891-6640(2007)21[113:eoantv]2.0.co;2 · Cited by 65
Rückert, R., Brandt, K., Ernst, M., Marienfeld, K., Csernok, E., Metzler, C., Budagian, V., Bulanova, E., Paus, R., & Bulfone‐Paus, S. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02878.x · Cited by 64
Faradji, A., Bohbot, A., Schmitt‐Goguel, M., Siffert, J.-C., Dumont, S., Wiesel, M. L., Piémont, Y., Eischen, A., Bergerat, J., Bartholeyns, J., et al. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90033-7 · Cited by 64
Sans-Fons, M. G., Yeramian, A., Pereira‐Lopes, S., Santamaria‐Babí, L. F., Modolell, M., Lloberas, J., & Celada, A. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit084 · Cited by 64
Roy, R. M., Wüthrich, M., & Klein, B. S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200689 · Cited by 64
Role of Tumor-Associated Macrophages in Sarcomas
Fujiwara, T., Healey, J. H., Ogura, K., Yoshida, A., Kondo, H., Hata, T., Kure, M., Tazawa, H., Nakata, E., Kunisada, T., et al. (2021) · Cancers · doi:10.3390/cancers13051086 · Cited by 64 · cited 1×
“Soft tissue sarcoma Variable, but generally high-grade disease and decreased DFS and OS (132, 133) High-grade disease and increased MI (134)”
BackgroundMeyers, P. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_11 · Cited by 64
Marconato, L., Martini, V., Stefanello, D., Moretti, P., Ferrari, R., Comazzi, S., Laganga, P., Riondato, F., & Aresu, L. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.07.009 · Cited by 63
Weiskopf, K., Anderson, K. L., Ito, D., Schnorr, P. J., Tomiyasu, H., Ring, A. M., Bloink, K., Efe, J. A., Rue, S. M., Lowery, D. E., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0105 · Cited by 63
Sun, N.-Y., Chen, Y.-L., Wu, W.-Y., Lin, H.-W., Chiang, Y.-C., Chang, C.-F., Tai, Y.-J., Hsu, H.-C., Chen, C.-A., Sun, W.-Z., et al. (2019) · Cancers · doi:10.3390/cancers11091400 · Cited by 62
Takahashi, K. (2001) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.41.1 · Cited by 61
The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
Huang, L., Ge, X., Liu, Y., Li, H., & Zhang, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061228 · Cited by 61
Manji, G. A., Van Tine, B. A., Lee, S. M., Raufi, A. G., Pellicciotta, I., Hirbe, A. C., Pradhan, J., Chen, A., Rabadan, R., & Schwartz, G. K. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1779 · Cited by 59
Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses
Sottnik, J. L., U’Ren, L., Thamm, D. H., Withrow, S. J., & DOW, S. W. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0755-y · Cited by 58
Self-citationHarrington, B. K., Gardner, H. L., Izumi, R., Hamdy, A., Rothbaum, W., Coombes, K. R., Covey, T., Kaptein, A., Gulrajani, M., Van Lith, B., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159607 · Cited by 58
Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma
Withers, S. S., Skorupski, K. A., York, D. S., Choi, J. W., Woolard, K., Amorim, R. L., Sparger, E. E., Rodriguez, C. O., McSorley, S. J., Monjazeb, A. M., et al. (2018) · Veterinary and Comparative Oncology · doi:10.1111/vco.12444 · Cited by 58 · cited 3×
“Osteosarcoma Increased OS and metastasis PFS in most studies; some exceptions noted (125–127) Increased DFI (128)”
BackgroundInfluentialColey’s Lessons Remembered: Augmenting Mistletoe Therapy
Orange, M., Reuter, U., & Hobohm, U. (2016) · Integrative Cancer Therapies · doi:10.1177/1534735416649916 · Cited by 57
Cryo-thermal therapy induces macrophage polarization for durable anti-tumor immunity
He, K., Jia, S., Lou, Y., Liu, P., & Xu, L. X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1459-7 · Cited by 56
Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1
Nemoto, Y., Shosu, K., Okuda, M., Noguchi, S., & Mizuno, T. (2018) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2018.02.007 · Cited by 55
Virtakoivu, R., Rannikko, J. H., Viitala, M., Vaura, F., Takeda, A., Lönnberg, T., Koivunen, J., Jaakkola, P., Pasanen, A., Shetty, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4862 · Cited by 55
Mannheimer, J., Tawa, G. J., Gerhold, D. L., Braisted, J. C., Sayers, C. M., McEachron, T. A., Meltzer, P. S., Mazcko, C. N., Beck, J. A., & LeBlanc, A. K. (2023) · Communications Biology · doi:10.1038/s42003-023-05208-z · Cited by 55
Fisher, G. A., Lakhani, N. J., Eng, C., Hecht, J. R., Bendell, J. C., Philip, P. A., O'Dwyer, P. J., Johnson, B., Kardosh, A., Ippolito, T. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.114 · Cited by 53
Monnier, M., Paolini, L., Vinatier, E., Mantovani, A., Delneste, Y., & Jeannin, P. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005560 · Cited by 53
Prognostic value of tumour‐associated macrophages in canine mammary tumours
Raposo, T. P., Gregório, H., Pires, I. C. R., Prada, J., & QUEIROGA, F. L. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00326.x · Cited by 52 · cited 1×
“Calprotectin/ MAC387 M1, TAMs, recently recruited macrophages (123, 131, 137, 139, 144, 166, 168)”
The Role of Tumor-Associated Macrophages in Leukemia
Li, Y., You, M. J., Yang, Y., Hu, D., & Tian, C. (2019) · Acta Haematologica · doi:10.1159/000500315 · Cited by 52 · cited 1×
“Although most intuitive with solid tumors, blood-borne cancers also maintain a TME composed of a diversity of cells (80).”
BackgroundSutton, T. L., Patel, R. K., Anderson, A. N., Bowden, S. G., Whalen, R. M., Giske, N. R., & Wong, M. H. (2022) · Cancers · doi:10.3390/cancers14163871 · Cited by 52
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present
Denny, W. A., & Flanagan, J. U. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1839414 · Cited by 50
Two Faces of Macrophages: Training and Tolerance
Zubair, K., You, C., Kwon, G., & Kang, K. (2021) · Biomedicines · doi:10.3390/biomedicines9111596 · Cited by 50
Seung, B., Lim, H., Shin, J.-I., Kim, H.-W., Cho, S., Kim, S., & Sur, J. (2018) · Veterinary Pathology · doi:10.1177/0300985817750457 · Cited by 49
THE TRANSFORMATION OF WHITE BLOOD CELLS
Lewis, M. R., & Lewis, W. H. (1925) · JAMA · doi:10.1001/jama.1925.02660370008002 · Cited by 47
CHEN, Y., XU, S.-F., XU, M., & YU, X.-C. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.528 · Cited by 47
Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs
Hafeman, S., London, C. A., Elmslie, R. E., & DOW, S. W. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0763-y · Cited by 47
Kurzman, I. D., Shi, F., Vail, D. M., & MacEwen, E. G. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.121 · Cited by 46
Thamm, D. H., Kurzman, I. D., Clark, M. A., Ehrhart, E. J., Kraft, S. L., Gustafson, D. L., & Vail, D. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2804 · Cited by 46
Self-citationWagner, A., Junginger, J., Lemensieck, F., & Hewicker‐Trautwein, M. (2018) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2018.01.011 · Cited by 46
Raposo, T. P., Pires, I. C. R., Carvalho, M. I., Prada, J., Argyle, D. J., & QUEIROGA, F. L. (2013) · Veterinary and Comparative Oncology · doi:10.1111/vco.12067 · Cited by 45
Li, F., Okreglicka, K. M., Pohlmeier, L. M., Schneider, C., & Kopf, M. (2020) · The EMBO Journal · doi:10.15252/embj.2019103205 · Cited by 44
Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma
Laver, T., London, C. A., Vail, D. M., Biller, B. J., Coy, J., & Thamm, D. H. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12328 · Cited by 42
Self-citationSpitzbarth, I., Moore, S. A., Stein, V. M., Levine, J. M., Kühl, B., Gerhauser, I., & Baumgärtner, W. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.595796 · Cited by 42
Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector
Musser, M. L., Berger, E. P., Tripp, C. D., Clifford, C. A., Bergman, P. J., & Johannes, C. M. (2020) · Veterinary and Comparative Oncology · doi:10.1111/vco.12642 · Cited by 41
Macewen, E. G., Kurzman, I. D., Helfand, S., Vail, D., London, C., Kisseberth, W., Rosenthal, R. C., Fox, L. E., Keller, E. T., Obradovich, J., et al. (1994) · Journal of Drug Targeting · doi:10.3109/10611869408996814 · Cited by 40
Naturally Occurring Canine Glioma as a Model for Novel Therapeutics
Hubbard, M. E., Arnold, S. A., Zahid, A. B., McPheeters, M. J., O’Sullivan, M. G., Tăbăran, F., Hunt, M. A., & Pluhar, G. E. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1514622 · Cited by 40
Rebhun, R. B., York, D. S., Cruz, S. M., Judge, S. J., Razmara, A. M., Farley, L. E., Brady, R. V., Johnson, E. G., Burton, J. H., Willcox, J. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004493 · Cited by 40
Self-citationPatil, S., Gentschev, I., Adelfinger, M., Donat, U., Heß, M., Weibel, S., Nolte, I. J. A., Frentzen, A., & Szalay, A. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047472 · Cited by 39
Effects of intravenous BCG in normal dogs and in dogs with spontaneous osteosarcoma
Owen, L. N., & Bostock, D. E. (1974) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(74)90133-9 · Cited by 39
Król, M., Pawłowski, K., Majchrzak, K., Gajewska, M., Majewska, A., & Motyl, T. (2012) · BMC Veterinary Research · doi:10.1186/1746-6148-8-16 · Cited by 37
Wang, X., Xu, Y., Sun, Q., Zhou, X., Ma, W., Wu, J., Zhuang, J., & Sun, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113343 · Cited by 36
Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target
Gingrich, A. A., Reiter, T. E., Judge, S. J., York, D. S., Yanagisawa, M., Razmara, A. M., Sturgill, I. R., Basmaci, U. N., Brady, R. V., Stoffel, K. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670309 · Cited by 35
Self-citationWang, C., Lin, Y., Zhu, H., Zhou, Y., Mao, F., Huang, X., Sun, Q., & Li, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905846 · Cited by 35
Canine mammary cancer cells direct macrophages toward an intermediate activation state between M1/M2
Beirão, B. C. B., Raposo, T. P., Pang, L. Y., & Argyle, D. J. (2015) · BMC Veterinary Research · doi:10.1186/s12917-015-0473-y · Cited by 34
Guo, L., Zhang, Y., Wei, R., Wang, C., & Feng, M. (2019) · Theranostics · doi:10.7150/thno.37380 · Cited by 34
IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice
Jackaman, C., Dye, D. E., & Nelson, D. J. (2014) · AGE · doi:10.1007/s11357-014-9655-y · Cited by 33
Characterization of Immune Cell Infiltration Into Canine Intracranial Meningiomas
Boozer, L. B., Davis, T., Borst, L. B., Zseltvay, K. M., Olby, N. J., & Mariani, C. L. (2011) · Veterinary Pathology · doi:10.1177/0300985811417249 · Cited by 33
In Vivo MR Imaging of Tumor-Associated Macrophages: The Next Frontier in Cancer Imaging
Yang, R., Sarkar, S., Yong, V. W., & Dunn, J. F. (2018) · Magnetic Resonance Insights · doi:10.1177/1178623x18771974 · Cited by 33
Immunohistochemical evaluation of immune cell infiltration in canine gliomas
Krane, G. A., O’Dea, C. A., Malarkey, D. E., Miller, A. D., Miller, C. R., Tokarz, D. A., Jensen, H. L., Janardhan, K. S., Shockley, K. R., Flagler, N. D., et al. (2021) · Veterinary Pathology · doi:10.1177/03009858211023946 · Cited by 33 · cited 3×
“Frontiers in Immunology 07 gliomas, lymphoma, soft tissue sarcomas and mast cell tumors (123, 124, 131, 134, 171, 173).”
BackgroundAmmons, D. T., Guth, A., Rozental, A. J., Kurihara, J. N., Marolf, A. J., Chow, L., Griffin, J. F., Makii, R. L., MacQuiddy, B., Boss, M., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0388 · Cited by 33
Hafeman, S., Varland, D., & DOW, S. W. (2011) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2011.00274.x · Cited by 32
Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma
Withers, S. S., York, D. S., Choi, J. W., Woolard, K., Amorim, R. L., Sparger, E. E., Burton, J. H., McSorley, S. J., Monjazeb, A. M., Murphy, W. J., et al. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12459 · Cited by 32
Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft‐tissue sarcoma
Guth, A., Hafeman, S., Elmslie, R. E., & DOW, S. W. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00319.x · Cited by 31
Nielsen, L. N., Kjelgaard-Hansen, M. J., & Kristensen, A. T. (2013) · The Veterinary Journal · doi:10.1016/j.tvjl.2013.07.030 · Cited by 31
Extracellular Matrix from Porcine Small Intestinal Submucosa (SIS) as Immune Adjuvants
Aachoui, Y., & Ghosh, S. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027083 · Cited by 31
Engineering Macrophages via Nanotechnology and Genetic Manipulation for Cancer Therapy
Ding, X., Sun, X., Cai, H., Wu, L., Liu, Y., Zhao, Y., Zhou, D., Yu, G., & Zhou, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.786913 · Cited by 31
Fastrès, A., Pirottin, D., Fiévez, L., Tutunaru, A.-C., Bolen, G., Merveille, A., Marichal, T., Desmet, C. J., Bureau, F., & Clercx, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611749 · Cited by 30
Porcellato, I., Sforna, M., Giudice, A. L., Bossi, I., Musi, A., Tognoloni, A., Chiaradia, E., Mechelli, L., & Brachelente, C. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.878949 · Cited by 30
Teske, E., Rutteman, G. R., van den Ingh, T. S. G. A. M., van Noort, R., & Misdorp, W. (1998) · PubMed · Cited by 29
Fidler, I. J., Fogler, W. E., Schroit, A. J., Schumann, G., Braun, D. G., & Schroit, A. J. (1983) · Elsevier eBooks · doi:10.1016/b978-0-08-029775-0.50035-3 · Cited by 29
Lucroy, M. D., Clauson, R. M., Suckow, M. A., El-Tayyeb, F., & Kalinauskas, A. E. (2020) · BMC Veterinary Research · doi:10.1186/s12917-020-02675-y · Cited by 29
Association of Canine Osteosarcoma and Monocyte Phenotype and Chemotactic Function
Tuohy, J. L., Lascelles, B. D. X., Griffith, E. H., & Fogle, J. E. (2016) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.13983 · Cited by 28
Woldemeskel, M., Hawkins, I. K., & Whittington, L. (2017) · BMC Veterinary Research · doi:10.1186/s12917-017-1030-7 · Cited by 28
Herrmann, I., Gotovina, J., Fazekas-Singer, J., Fischer, M., Hufnagl, K., Bianchini, R., & Jensen-Jarolim, E. (2018) · Developmental and Comparative Immunology · doi:10.1016/j.dci.2018.01.005 · Cited by 28 · cited 1×
“Reverse transcriptionquantitative polymerase chain reaction did show expected changes such as the upregulation of pro-inflammatory genes in the M1 subtype (73).”
BackgroundLin, M., Ma, S., Sun, L., & Qin, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1094400 · Cited by 28
Evolution of Cell-Autonomous Effector Mechanisms in Macrophages versus Non-Immune Cells
Gaudet, R. G., Bradfield, C. J., & MacMicking, J. D. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0050-2016 · Cited by 27 · cited 1×
“Macrophages are ancient, phagocytic immune cells thought to have their origins 500 million years ago in metazoan phylogeny (1).”
BackgroundPrognostic histopathologic features of canine glial tumors
Merickel, J. L., Pluhar, G. E., Rendahl, A., & O’Sullivan, M. G. (2021) · Veterinary Pathology · doi:10.1177/03009858211025795 · Cited by 27
Mitochondrial DNA on Tumor-Associated Macrophages Polarization and Immunity
Guo, Y., Tsai, H., Zhang, L., & Zhu, H. (2022) · Cancers · doi:10.3390/cancers14061452 · Cited by 27
Fastrès, A., Pirottin, D., Fiévez, L., Marichal, T., Desmet, C. J., Bureau, F., & Clercx, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01707 · Cited by 26
Duong, L., Pixley, F. J., Nelson, D. J., & Jackaman, C. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.848925 · Cited by 26
Faulhaber, E. A., Janik, E. A., & Thamm, D. H. (2021) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16212 · Cited by 25
Self-citationChambers, M. R., Foote, J. B., Bentley, R. T., Botta, D., Crossman, D. K., Manna, D. L. D., Estévez-Ordoñez, D., Koehler, J. W., Langford, C. P., Miller, M. A., et al. (2021) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.31 · Cited by 25
Tumor-associated macrophages related signature in glioma
Wang, L.-J., Xue, Y., & Lou, Y. (2022) · Aging · doi:10.18632/aging.203968 · Cited by 25
Role of monocyte recruitment in hemangiosarcoma metastasis in dogs
Regan, D. P., Escaffi, A., Coy, J., Kurihara, J. N., & DOW, S. W. (2016) · Veterinary and Comparative Oncology · doi:10.1111/vco.12272 · Cited by 24
Poulin, L. F., Lasseaux, C., & Chamaillard, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00823 · Cited by 24 · cited 1×
“Other DC subsets likely differentiate from a very early branch point off early myeloid progenitors (24, 25).”
BackgroundKonduri, V., Halpert, M. M., Baig, Y. C., Coronado, R. E., Rodgers, J. R., Levitt, J. M., Cerroni, B., Piscoya, S., Wilson, N., DiBernardi, L., et al. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0080-3 · Cited by 24
Lokhonina, А. V., Elchaninov, A. V., Fatkhudinov, T., Макаров, А. В., Arutyunyan, I. V., Grinberg, M., Glinkina, V. V., Surovtsev, V. V., Bolshakova, G. B., Goldshtein, D. V., et al. (2019) · BioMed Research International · doi:10.1155/2019/3912142 · Cited by 24 · cited 1×
“Ontogeny, and not just external stimuli, has been established as an important contributing factor to how macrophages respond to physiologic and pathologic stimuli, underlying the importance of further understanding in this area (43, 44).”
BackgroundPotential PET tracers for imaging of tumor-associated macrophages
Fernandes, B., Feltes, P. K., Luft, C., Nazario, L. R., Jeckel, C. M. M., Antunes, I. F., Elsinga, P. H., & de Vries, E. F. J. (2022) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-022-00163-2 · Cited by 24
Al‐Nadaf, S., Rebhun, R. B., Curran, K. M., Venable, R. O., Skorupski, K. A., Willcox, J. L., & Burton, J. H. (2018) · BMC Veterinary Research · doi:10.1186/s12917-018-1688-5 · Cited by 23
Killion, J. J., & Fidler, I. J. (1994) · ImmunoMethods · doi:10.1006/immu.1994.1029 · Cited by 22
Mukaratirwa, S., Chitanga, S., Chimatira, T., Makuleke, C., Sayi, S., & Bhebhe, E. (2009) · Journal of the South African Veterinary Association · doi:10.4102/jsava.v80i2.178 · Cited by 22
Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs
Yannelli, J. R., Wouda, R. M., Masterson, T. J., Avdiushko, M. G., & Cohen, D. A. (2016) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2016.10.011 · Cited by 22
Parisi, F., Tesi, M., Millanta, F., Gnocchi, M., & Poli, A. (2021) · Research in Veterinary Science · doi:10.1016/j.rvsc.2021.02.007 · Cited by 22
Ayers, J., Milner, R. J., Cortés-Hinojosa, G., Riva, A., Axiak‐Bechtel, S. M., Sahay, B., Cascio, M., Lejeune, A. T., Shiomitsu, K., Souza, C. H. M., et al. (2021) · Journal of Veterinary Diagnostic Investigation · doi:10.1177/1040638720985242 · Cited by 21
Toedebusch, R. G., Grodzki, A. C., Dickinson, P. J., Woolard, K., Vinson, N., Sturges, B. K., Snyder, J., Li, C., Nagasaka, O., Consales, B., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab062 · Cited by 21 · cited 2×
“Frontiers in Immunology 07 gliomas, lymphoma, soft tissue sarcomas and mast cell tumors (123, 124, 131, 134, 171, 173).”
BackgroundCanine polarized macrophages express distinct functional and transcriptomic profiles
Chow, L., Soontararak, S., Wheat, W. H., Ammons, D. T., & DOW, S. W. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.988981 · Cited by 21 · cited 1×
“RNA-sequencing (RNA-seq) was used to identify unique canine gene signatures of polarized macrophages, resulting in 6 distinct clusters of macrophage genes (74).”
MethodVenturin, G. L., Chiku, V. M., Silva, K. L. O., de Almeida, B. F. M., & de Lima, V. M. F. (2016) · Parasite Immunology · doi:10.1111/pim.12353 · Cited by 20
Hans, E. C., Pinard, C. J., van Nimwegen, S. A., Kirpensteijn, J., Singh, A., MacEachern, S. N., Naber, S. J., & Dudley, R. M. (2018) · Veterinary Surgery · doi:10.1111/vsu.13105 · Cited by 18
Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages
Gulay, K. C. M., Aoshima, K., Maekawa, N., Suzuki, T., Konnai, S., Kobayashi, A., & Kimura, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-06203-w · Cited by 18
Rybicka, A. M., Eyileten, C., Taciak, B., Mucha, J., Majchrzak, K., Hellmén, E., & Król, M. (2016) · PubMed · Cited by 16
Jackson, K., Milner, R. J., Doty, A. L., Hutchison, S., Cortés-Hinojosa, G., Riva, A., Sahay, B., Lejeune, A. T., & Axiak‐Bechtel, S. M. (2020) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2020.110144 · Cited by 16
Marconato, L., Melacarne, A., Aralla, M., Sabattini, S., Tiraboschi, L., Ferrari, V., Zeira, O., Balboni, A., Faroni, E., Guerra, D., et al. (2022) · Cancers · doi:10.3390/cancers14051347 · Cited by 16
Macrophage numbers in the marginal area of sarcomas predict clinical prognosis
Umakoshi, M., Nakamura, A., Tsuchie, H., Li, Z., Kudo‐Asabe, Y., Miyabe, K., Ito, Y., Yoshida, M., Nagasawa, H., Okada, K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28024-1 · Cited by 16 · cited 1×
“Soft tissue sarcoma Variable, but generally high-grade disease and decreased DFS and OS (132, 133) High-grade disease and increased MI (134)”
BackgroundImmunohistochemical Characterization of Tumor-Associated Macrophages in Canine Lymphomas
Vázquez, S., Vallejo, R., Espinosa, J., Arteche-Villasol, N., Vega, J. A., & Pérez, V. P. (2021) · Animals · doi:10.3390/ani11082301 · Cited by 15 · cited 3×
“Frontiers in Immunology 07 gliomas, lymphoma, soft tissue sarcomas and mast cell tumors (123, 124, 131, 134, 171, 173).”
BackgroundAdvances in Single-Cell Multi-Omics and Application in Cardiovascular Research
Zhang, X., Qiu, H., Zhang, F., & Ding, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.883861 · Cited by 15
Finotello, R., Whybrow, K., Scarin, G., & Ressel, L. (2021) · Animals · doi:10.3390/ani11030684 · Cited by 14 · cited 2×
“Frontiers in Immunology 07 gliomas, lymphoma, soft tissue sarcomas and mast cell tumors (123, 124, 131, 134, 171, 173).”
BackgroundIntralesional Bacillus Calmette-Guérin immunotherapy of canine venereal tumors.
Hess, A. D., Catchatourian, R., Zander, A. R., & Epstein, R. B. (1977) · PubMed · Cited by 13
Herstad, K. M. V., Gunnes, G., Rørtveit, R., Kolbjørnsen, Ø., Tran, L., & Skancke, E. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02829-6 · Cited by 13
Fan, T. T., Li, C., & He, J. (2021) · Biology of Sex Differences · doi:10.1186/s13293-021-00406-y · Cited by 12
Costa, V. R., Soileau, A. M., Liu, C., Moeller, C. E., Carossino, M., Langohr, I. M., & Withers, S. S. (2022) · Research in Veterinary Science · doi:10.1016/j.rvsc.2022.04.005 · Cited by 11
Guldner, D., Hwang, J. K., Cardieri, M. C. D., Eren, M. V., Ziaei, P., Norton, M. G., & Souza, C. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165477 · Cited by 9
Eto, S., Yanai, H., Hangai, S., Kato, D., Nishimura, R., & Nakagawa, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-87979-1 · Cited by 8 · cited 1×
“Frontiers in Immunology 06 This was hypothesized to be one mechanism by which dysregulation of the response to inflammation may contribute to tumorigenesis (115).”
BackgroundSingle-cell T-cell receptor repertoire profiling in dogs
Hoang, M., Skidmore, Z. L., Rindt, H., Chu, S., Fisk, B. A., Foltz, J. A., Fronick, C. C., Fulton, R. S., Zhou, M., Bivens, N. J., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06174-w · Cited by 8
Proksch, S., Matthysen, C. P., Jardine, J. E., Wyatt, K., Finlay, J. R., & Nelson, D. J. (2022) · Veterinary and Comparative Oncology · doi:10.1111/vco.12813 · Cited by 7
Vieira-Filho, C. H. D. C., Barrouin‐Melo, S. M., Damasceno, K. A., Araújo, M. S. S., Borges, N. F., Silva, F. L., Cassali, G. D., & Estrela‐Lima, A. (2018) · Pesquisa Veterinária Brasileira · doi:10.1590/1678-5150-pvb-5638 · Cited by 5
Canine osteosarcoma failure of intravenous or intralesional BCG as adjuvant immunotherapy
Weiden, P. L., Deeg, H. J., Graham, T. C., & Storb, R. F. (1981) · Cancer Immunology Immunotherapy · doi:10.1007/bf00205777 · Cited by 4
A blocking antibody against canine CSF-1R maturated by limited CDR mutagenesis
Beirão, B. C. B., Raposo, T. P., Imamura, L. M., Ingberman, M., Hupp, T. R., Vojtěšek, B., & Argyle, D. J. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa018 · Cited by 3
Hematologic and clinical characteristics of dogs with circulating macrophage‐like cells
Mochizuki, H., & Stowe, D. M. (2021) · Veterinary Clinical Pathology · doi:10.1111/vcp.12962 · Cited by 3
Soileau, A. M., Quick, C. N., Moeller, C. E., Schaumburg, J. C., & Withers, S. S. (2022) · Veterinary Sciences · doi:10.3390/vetsci9070374 · Cited by 3
Single Cell T Cell Receptor Repertoire Profiling for DogsPreprint
Skidmore, Z. L., Rindt, H., Chu, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.29.450365 · Cited by 2
Mannheimer, J., Tawa, G. J., Gerhold, D. L., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2331111/v1 · Cited by 1
Hashimoto, K. (1971) · Archives of Dermatology · doi:10.1001/archderm.1971.04000200036007
Research works printed but not linked: 2
- Macewen EG Kurzman ID Helfand S Vail D London C Kisseberth W. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: A progress review*. J Drug Target (1994) 2: 391–6. doi: 10.3109/10611869408996814 7704483 · DOI · Paper page
- Gordon SR Maute RL Dulken BW Hutter G George BM McCracken MN. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity. Nature (2017) 545: 495. doi: 10.1038/NATURE22396 28514441 PMC5931375 · DOI · Paper page
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Moreover, engineered CAR-Ms have leaded to increase of anti-tumor cytokines, such as IL-6, and chemokines, such as CXCL18, in the TME of osteosarcoma [138, 139].”
BackgroundTumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy
Saeed, A. F. U. H. (2025) · Cells · doi:10.3390/cells14100741 · Cited by 112
“Macrophages express dissociated CRT, forming the CRT/CD91/C1q complexes, allowing them to phagocytose cancer cells [109].”
Shao, S., Miao, H., & Ma, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295684 · Cited by 70
Mengistu, B. A., Tsegaw, T., Demessie, Y., Getnet, K., Bitew, A. B., Kinde, M. Z., Berihun, A. M., Mebratu, A. S., Mekasha, Y. T., Feleke, M. G., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03558-0 · Cited by 85
Targeting Macrophage Polarization for Reinstating Homeostasis following Tissue Damage
Du, Q., Dickinson, A., Nakuleswaran, P., Maghami, S., Alagoda, S., Hook, A. L., & Ghaemmaghami, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137278 · Cited by 60
“The recognition of macrophages in regulating these processes has underpinned the emergence of many approaches focused on rebalancing immune homeostasis to support tissue repair by targeting macrophage polarization to enhance immune-mediated tissue regeneration [17,21–30].”
Background
Metadata
- Authors
- Brady, R. V., & Thamm, D. H.
- Affiliations
- Colorado State University (US)
- Corresponding author
- Thamm, Douglas H.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-04-05
- Volume
- 14
- Pages
- 1176807-1176807
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC10113558
- OpenAlex
- W4362637748
- Cited by
- 35
- References
- 329
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 14 · 2023: 2
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- American Kennel Club Canine Health Foundation (03033-E)
- Morris Animal Foundation (D22CA-500)
- National Institutes of Health (2T32OD010437-21)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- tumor-associated macrophages, macrophage plasticity, tumor microenvironment, immunosuppression, pet dogs, dogs as cancer models, macrophage phenotype, macrophage origin
- MeSH terms
- Tumor-Associated Macrophages, Animals, Dogs, Humans, Macrophages, Neoplasms, Prognosis, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.